UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the period ended September 30, 2005
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________________ to ______________________.
Commission file number 0-31198
STELLAR PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
ONTARIO, CANADA | | N/A |
(State or Other Jurisdiction of Incorporation or Organization) | | (I.R.S. Employer Identification No.) |
544 Egerton St
London, Ontario Canada
N5W 3Z8
(Address of principal executive offices)
(519) 434-1540
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No
The number of outstanding common shares, no par value, of the Registrant at:
September 30, 2005: 23,265,662
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned thereunto duly authorized.
| | | |
| | STELLAR PHARMACEUTICALS INC. |
|
|
|
| Date: November 11, 2005 | | By: /s/ Peter Riehl |
| |
Name: Peter Riehl Title: Chief Executive Officer |
| | |
